The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Immunol
Hlavní autoři: Ren, Sijia, Xiong, Xinxin, You, Hua, Shen, Jianfei, Zhou, Penghui
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Immunology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8206805/
https://ncbi.nlm.nih.gov/pubmed/34149730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.689132
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky